Skip to main content
Explore URMC

Wilmot Cancer Institute Logo

menu
Archibald S. Perkins, M.D., Ph.D.
Archibald S. Perkins, M.D., Ph.D.

Archibald S. Perkins, M.D., Ph.D.

Pathology/Lab Medicine — Anatomic Pathology — Anatomic Pathology

Accepting New Patients

Archibald S. Perkins, M.D., Ph.D.

Pathology/Lab Medicine — Anatomic Pathology — Anatomic Pathology

Accepting New Patients


Locations

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 626
Rochester, NY 14642
Get Directions

phone

Appointments

(585) 275-8762

print

Fax

(585) 756-4468

About Me

Dr. Perkins is an active participant in the clinical hematopathology service as well as a researcher exploring the genes that impact the development of leukemias and other human malignancies. His primary focus is acute myeloid leukemia (AML), a particularly lethal type of cancer with no effective therapies at present. His clinical responsibilities include interpretation of bone marrow biopsies and smears, lymph node biopsies, and spleen; and laboratory analyses of coagulation disorders and hemoglobinopathies.

Credentials

Education:

MD, PhD | Columbia University College of Physicians and Surg — 1986

Post-doctoral Training & Residency:

Residency in Pathology at Brigham & Women's Hospital — 1986 - 1988
Fellowship in Genetics at National Cancer Institute — 1988 - 1992

Research

Dr. Perkins' current research focus is on Evi1, a complex locus that plays a critical role in both normal Hematopoiesis and myeloid leukemogenesis. Evidence indicates that Evi1 is an important player in maintenance of the leukemic stem cell compartment by increasing proliferation and prolonging survival, in part through regulation of the transcription factor Gata2 and the anti-apoptotic molecule Bc12a1. His current work encompasses embryogenesis in genetically modified mice, identification of chromosomal Evi1 binding targets, Evi1 protein-protein interactions, clinical implications of chromosomal rearrangements involving Evi1, and exploration of potential therapeutic approaches to block the function of Evi1 in leukemia.

Publications:

Juneja SC, Vonica A, Zeiss C, Lezon-Geyda K, Yatsula B, Sell DR, Monnier VM, Lin S, Ardito T, Eyre D, Reynolds D, Yao Z, Awad HA, Yu H, Wilson M, Honnons S, Boyce BF, Xing L, Zhang Y, Perkins AS. "Deletion of Mecom in mouse results in early-onset spinal deformity and osteopenia." Bone.. 2014 Mar 0; 60:148-61. Epub 2013 Dec 04.

Glass C, Wilson M, Gonzalez R, Zhang Y, Perkins AS. "The role of EVI1 in myeloid malignancies." Blood cells, molecules & diseases.. 2014 53(1-2):67-76. Epub 2014 Feb 01.

Bard-Chapeau EA, Szumska D, Jacob B, Chua BQ, Chatterjee GC, Zhang Y, Ward JM, Urun F, Kinameri E, Vincent SD, Ahmed S, Bhattacharya S, Osato M, Perkins AS, Moore AW, Jenkins NA, Copeland NG. "Mice carrying a hypomorphic Evi1 allele are embryonic viable but exhibit severe congenital heart defects." PloS one. 2014 9(2):e89397. Epub 2014 Feb 27.

View All Publications

Links:

Cancer research, using mouse models to investigate molecular mechanisms in acute myeloid leukemia and myelodysplastic syndrome, with focus on the function of the zinc finger oncoprotein EVI1.